Our mission is to enable and invest in brilliant and determined health and life sciences professionals to build global ventures from the ground up. This program is aimed to expand on our previous success in acceleration to life sciences startups to the Kingdom and GCC region.
Dr. Sergei Petukhov, is a seasoned biotech investor, board member / board observer on number of private and public biotech companies.
Sergei has an extensive experience in generating a highly profitable deal-flow pipeline by investing in early stage assets. He participated in Series A/B biotechnology investments and led the development of startup companies to the successful “unicorn” IPO and M&A exits valued at over $2B.
He took board positions at EV’s portfolio companies including: Seres Therapeutics ($1.9B IPO), Axcella ($459.8M IPO), Egalet ($167M IPO) Cavion ($321.2M M&A), Galera Therapeutics ($310M IPO), Cellectar Biosciences, NeuroVia and Monet Pharmaceuticals.
Prior to EV, Dr. Petukhov was a Managing Director at CLS Capital and was an advisor at Kaye Scholer LLP for a number of US and EU pharmaceutical companies on matters related to IP and patent litigation.
Dr. Petukhov worked at RUSNANO PE/VC fund aimed at commercializing developments in nanotechnology.
Dr. Petukhov worked and studied at The Rockefeller University, The University of Edinburgh, The University of Cambridge, Moscow 1st Medical Academy and Moscow Academy of Veterinary Medicine and Biotechnology.
Dr. Gaymalov is an experienced healthcare innovation leader with a passion for translating early-stage research into clinical practice.
Dr. Gaymalov’s scientific background includes critical research and development roles of increasing responsibility across the healthcare and life sciences product development spectrum, from pre-clinical research to clinical development of treatments, drugs, medical devices, and software applications.
He is the inventor of a DNA-based gene treatment of ischemic conditions, and with a team of physicians and scientists at UNMC, he perfected the polymer-based gene therapy of hind limb ischemia that accelerated its adoption in clinical practice today.
Gaymalov is the inventor of a commercial assessment methodology (ICANVAS®️) that is currently used by NASA, DARPA, NIST, and Fortune 500 companies. He is also a co-inventor of a reverse conceptual product engineering methodology (RECOPE®️) for developing commercialization strategies to bring healthcare innovations from academia to market without compromising the academic ingenuity practiced by esteemed healthcare organizations like University of Nebraska Medical Center (UNMC), the University of North Carolina at Chapel Hill (UNC-CH), Imam Abdulrahman Bin Faisal University, and others. Last but not least, Dr. Gaymalov founded several healthcare startups that developed pharmaceutical, diagnostic, nutraceutical, cosmetics, wellness, and digital health products.